Advances of using sirolimus to treat venous malformations

doi:10.19438/j.cjoms.2020.06.001

Abstract

Abstract: Venous malformations are the most common vascular malformations seen in the clinic, most of them are caused by gain-of-function somatic mutations in the genes encoding TIE2 or PI3K. Management of complicated or refractory lesions is still a great challenge for clinicians. mTOR inhibitor sirolimus is the first targeting agent for venous malformation treatment, its efficacy and safety have attracted much attention in recent years. This article reviewed the related problems and advances of using sirolimus to treat venous malformationsl.

Key words: Venous malformations, Sirolimus, Rapamycin, mTOR inhibitor, Targeted molecular therapy

CLC Number:

R739.8

ZHENG Jia-wei. Advances of using sirolimus to treat venous malformations[J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(6): 553-558.

References

[1] Uebelhoer M, Boon LM, Vikkula M.Vascular anomalies: from genetics toward models for therapeutic trials[J]. Cold Spring Harb Perspect Med, 2012, 2(8): a009688.
[2] Soblet J, Kangas J, Nätynki M, et al.Blue Rubber Bleb Nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations[J]. J Invest Dermatol, 2017, 137(1): 207-216.
[3] 国际血管联盟中国分部血管畸形专家委员会.静脉畸形中国专家共识[J].介入放射学杂志,2019,28(3):307-311.
[4] Dompmartin A, Acher A, Thibon P, et al.Association of localized intravascular coagulopathy with venous malformations[J]. Arch Dermatol, 2008, 144(7): 873-877.
[5] Boon LM, Vanwijck R.Medical and surgical treatment of venous malformations[J]. Ann Chir Plast Esthet, 2006, 51(4-5): 403-411.
[6] Boutouja F, Stiehm CM, Platta HW. mTOR: a cellular regulator interface in health and disease[J]. Cells, 2019, 8(1): 18-41.
[7] Hu HT, Huang YH, Chang YA, et al.Tie2-R849W mutant in venous malformations chronically activates a functional STAT1 to modulate gene expression[J]. J Invest Dermatol, 2008, 128(9): 2325-2333.
[8] Soblet J, Limaye N, Uebelhoer M, et al.Variable somatic TIE2 mutations in half of sporadic venous malformations[J]. Mol Syndromol, 2013, 4(4): 179-183.
[9] Wouters V, Limaye N, Uebelhoer M, et al.Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects[J]. Eur J Hum Genet, 2010, 18(4): 414-420.
[10] Limaye N, Kangas J, Mendola A, et al.Somatic activating PIK3CA mutations cause venous malformation[J]. Am J Hum Genet, 2015, 97(6): 914-921.
[11] Castillo SD, Tzouanacou E, Zaw-Thin M, et al. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans [J]. Sci Transl Med, 2016, 8(332): 332ra43.
[12] Uebelhoer M, Nätynki M, Kangas J, et al.Venous malformation causative TIE2 mutations mediate an AKT dependent decrease in PDGF-b[J]. Hum Mol Genet, 2013, 22(17): 3438-3448.
[13] Nätynki M, Kangas J, Miinalainen I, et al.Common and specific effects of TIE2 mutations causing venous malformations[J]. Hum Mol Genet, 2015, 24(22): 6374-6389.
[14] Boscolo E, Limaye N, Huang L, et al.Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects[J]. J Clin Invest, 2015, 125(9): 3491-3504.
[15] di Blasio L, Puliafito A, Gagliardi PA, et al. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations[J]. Cell Death Dis, 2018, 9(2): 45-60.
[16] Castel P, Carmona FJ, Grego-Bessa J, et al. Somatic PIK3CA mutations as a driver of sporadic venous malformations[J]. Sci Transl Med, 2016, 8(332):332ra42.
[17] Hammer J, Seront E, Duez S, et al.Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase Ⅱ study[J]. Orphanet J Rare Dis, 2018, 13(1): 191-204.
[18] Seront E, Van Damme A, Boon LM, et al.Rapamycin and treatment of venous malformations[J]. Curr Opin Hematol, 2019, 26(3): 185-192.
[19] Janssens P, Dekeuleneer V, Van Damme A, et al.Angiosarcoma arising from congenital primary lymphedema[J]. Pediatr Dermatol, 2018, 35(6): e382-e388.
[20] Adams DM, Trenor CC, Hammill AM, et al.Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies[J]. Pediatrics, 2016, 137(2): e20153257.
[21] Fruman DA, Chiu H, Hopkins BD, et al.The PI3K pathway in human disease[J]. Cell, 2017, 170(4): 605-635.
[22] Venot Q, Blanc T, Rabia SH, et al.Targeted therapy in patients with PIK3CA-related overgrowth syndrome[J]. Nature, 2018, 558(7711): 540-546.